Here, we show that increased tumour αV expression is associating with worse immunotherapy-related progression-free survival (PFS) in anti-PD-(L)1-treated NSCLC patients, which correlates with the decreased density of CD103+CD8+ TIL. The gene discussed is CD8A; the disease is neoplasm.